CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News CytoDyn is  a   biotech which has been effective hard but unsuccessfully to develop an one-time therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix. In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in phrases […]

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has been effective hard but unsuccessfully to develop an one-time therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.

In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in phrases of prospective indications.

CytoDyn's inventories of leronlimab are actually building up, whether they will ever be used is an open question.


While CYDY  is actually dawdling, promote opportunities for leronlimab as a combination therapy in the curing of multi-drug-resistant HIV happen to be closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of my past several shares. The 1st CytoDyn article of mine, "CytoDyn: What to be able to Do When It's Too Good To Be True?", set away what follows prediction:

Instead I expect it to become a serial disappointer. CEO Pourhassan presented such an extremely marketing image in the Uptick Newswire interview that I came away with a poor viewpoint of the business.

Irony of irony, the poor viewpoint of mine of the business has grown steadily, however, the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger yet still disappoints? Therein sits the story; permit me to explain.

CytoDyn acquired its much storied therapy (which I shall relate to as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc.... has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the treatment and reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV infected subjects. Today's payment of $3.5 million transfers ownership of the expertise and also linked intellectual property from Progenics to CytoDyn, and roughly twenty five million mg of bulk drug substance.... milestone payments after commencement of a phase III clinical trial ($1.5 huge number of) and the first new drug application endorsement ($5 million), as well as royalty payments of five percent of net sales upon commercialization.

Since that time, CytoDyn's helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to get a market place cap > $3.5 billion. It's done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous indications and many therapies, it has this individual treatments and a "broad pipeline of indications" as it puts it. I call certain pipelines, "pipedots." In CytoDyn's situation it touts its leronlimab as a potentially advantageous therapy of dozens of indications.

The opening banner of its on the site of its (below) shows an energetic company with diverse interests albeit focused on leronlimab, multiple illness sorts, multiple publications and multiple delivering presentations.

Can it all be smoke cigarettes and mirrors? That's a question I have been asking myself through the really beginning of the interest of mine in this company. Judging by way of the multiples of thousands of several responses on listings accessible via Seeking Alpha's CytoDyn Summary page, I am much from alone in this question.

CytoDyn is a traditional battleground, or even some might say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label some negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *